The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
出版年份 2021 全文链接
标题
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-12-20
DOI
10.3389/fimmu.2021.793964
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of novel biomarkers in Hunner’s interstitial cystitis using the CIBERSORT, an algorithm based on machine learning
- (2021) Kaining Lu et al. BMC Urology
- Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma
- (2021) Kevin T Lynch et al. Journal for ImmunoTherapy of Cancer
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer
- (2020) Kyoko Yamaguchi et al. OncoImmunology
- Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives
- (2020) Yoshiyuki Akiyama et al. INTERNATIONAL JOURNAL OF UROLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- (2020) Jianjun Gao et al. NATURE MEDICINE
- Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies
- (2019) Yoshiyuki Akiyama et al. JOURNAL OF UROLOGY
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer
- (2019) Alessia Echarti et al. Cancers
- Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer
- (2019) Alfonso Gómez de Liaño Lista et al. EUROPEAN UROLOGY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
- (2018) Bernadett Szabados et al. EUROPEAN UROLOGY
- Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development
- (2018) David G. Hill et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
- (2018) Nick van Dijk et al. EUROPEAN UROLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Topography of cancer-associated immune cells in human solid tumors
- (2018) Jakob Nikolas Kather et al. eLife
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
- (2017) Florian Posch et al. OncoImmunology
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients
- (2015) Stine L Figenschau et al. BMC CANCER
- Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
- (2015) Nikhil S. Joshi et al. IMMUNITY
- Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline Amendment
- (2015) Philip M. Hanno et al. JOURNAL OF UROLOGY
- Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
- (2013) B Goeppert et al. BRITISH JOURNAL OF CANCER
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Lymphoid aggregates in Crohn's colitis and mucosal immunity
- (2013) Carlos A. Rubio et al. VIRCHOWS ARCHIV
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now